These recruited CD16-expressing NK92 cells to exert potent cytotoxicity against CD38-expressing tumor cell lines in vitro and primary multiple myeloma cells ex vivo, independent of the epitope bound on CD38. The gene discussed is FCGR3B; the disease is neoplasm.